dd Dec 20

WP	Responsible	Activities
WP0 DE/NL	[redacted]	**Coordination**
WP1 DE/NL	[redacted]	**Preparation of Call for Evidence (including questionnaire and information document) in agreement between MS**
	[redacted]	**Call for Evidence (all MS and ECHA with news alerts and websites of all MS with Link to Helpdesk webpage)**
		Preparation of Restriction option analysis document (all MS)
		RIME+ Dortmund
		1st draft of restriction option analysis document (all MS)
		2nd draft of restriction option analysis document (all MS)
		Finalisation of document, i.e. clarification of restriction options and scope (all MS)
		Restriction option analysis document to be uploaded on CIRCA (DE/ NL CA)
		RMOA-Conclusion, PACT-Update
WP2 NL	[redacted]	**Drafting discussion paper**
		Wordt vragenlijst + aanvulling 1e discussion paper

		Verwerken commentaren van NO, SE, DE, I&W en RIVM deskundigen
WP3 DE/DK	**DE/DK** [redacted]	**Coordination and alignment** **Pre-phase for environmental and human health hazard assessment --> Overview of relevant hazards (besides persistence) and generation of draft lists of substances for assessment** **Assessment phase --> Draft text for restriction proposal**
WP4 NL/DE	[redacted]	
WP5 NO		Overview analytical methods (ch E7)
WP6 SE/DE	[redacted]	Overview human and environmental monitoring data Working plan Design template for collection of monitoring date Presentation of slide WP6 at RiME Meeting wieh NCSU Collect monitoring data - ENV Collect monitoring data - HUM RiME FEB-2021

WP7 NL	[redacted]	**Scoping essential use**
		Scoping impact assessment
		Baseline and restriction scenario(s)
		Economic impact assessment
		Environmental impact assessment
		Health impact assessment
		Assessment of other impacts
		Proportionality analysis

	starts
Monthly meetings	
2nd version questionnaire	
Draft of information document (DE/NL CA)	
Commenting round (all MS)	31-Mar-20
Revision and draft of 3rd version of questionnaire and information document for WebEx (DE/NL CA)	
Detailed discussion of questionnaire and information document (all MS) Webex	
Final version (DE/ NL CA)	
Notification into PACT (DE/ NL CA)	
	4-May-20
	May 2020
Discussion of responses received so far, data (all MS) Webex	
Decision on meetings with industry (all MS)	
Discussion of restriction scope and options (all MS) Webex	
Decision on which restriction options should be presented and discussed in RiME+ (all MS)	
Meetings with stakeholders and industry	August/Se
Presentation on RMOA for RiME	
	20/21 O
Contributions of first drafts of document parts according to lead in work packages and sub-work packages (all MS)	
Merge of contributions, redrafting (DE/ NL CA)	25-Sep-20
Redrafting by all MS	5-Oct-20
Merge of contributions, redrafting (DE/ NL CA)	19-Oct-20
Last redrafting by all MS	26-Oct-20
Finalisation (DE/ NL CA)	10-Nov-20
	23 – 27 No
Commenting (by all other MS not part of group)	1-Dec-20
Consideration of comments/if needed redrafting of document (DE/ NL CA in agreement with group)	4-Jan-21
Webex meeting for initial discussing based on broad definition (NL, DE, SE, DK, NO, ECHA, COM)	
1st discussion paper prepared by NL	
Face-to-face meeting (NL, DE, SE, DK, NO, ECHA, COM) based on discussion paper	
2nd discussion paper prepared by NL (before RiME+)	

Discussion during RiME+ meeting
Final discussion paper prepared by NL
2021 - TO BE PREPARED

Kick-off meeting
Joint HH/ENV progress meetings
HH subgroup meetings
ENV subgroup meetings

	1 May 2020 1 Nov. 2020
Start up, Develop generic information basis for all sub-uses, structure of the sub-use reports (by WP7) - DONE	1-May-20
Kick-off meeting (Discussion of content of each sub-use to avoid overlaps and discussion of revision of list of sub-uses and discussion of ETH Zürich work) - DONE	1-Jun-20
Start up sub uses, Project plan fine tuning for sub-uses (and if needed tendering for consultants)	
Progress meeting after CfE is closed to check sub-uses, decide on stakeholder meetings (i.e. via mail)	
Stakeholder Meetings per sub-use: Follow up on information from CfE and to address knowledge gaps	1-Aug-20
~~Sub-use studies (including gap analysis)~~	~~1-Sep-20~~
~~Progress meeting~~	
~~Progress meeting~~	
Final reports consultants (& feedback to WP2)	
Integration of information (including gap analysis)	1-Mar-21
Additional studies (i.e. membranes, processing aids?)	1-Feb-21
Additional stakeholder meetings? (digital?)	1-Feb-21
Preparation of the Annexes to the restriction dossier	1-Aug-21
Text for Chapter E.7 "Practicality and monitorability" in Annex E of the restriction dossier (see also Appendix E.1 in PFHxA restriction dossier).	
Standalone report on analytical methods for PFASs	
Optionally, the consultant may publish the overview as a scientific review article at its own costs in addition to the other deliverables	
Draft report	5/1/2020
Both human biomonitoring and environmental (bio)monitoring data	9/1/2020
Request to MSs to share monitoring data (incl. delivery of template)	
Share info on ongoing projects an monitoring data; (Jane Hoppin/Det	11/15/2020
DE ([redacted], [redacted]/NL ([redacted]) -> yuse reviews for "common' PFAS, collect specific data on more opscure PFASs as support for broad restricion of PFASs	

Literature review on ‘essential use’ by RIVM	1-May-20
Define criteria characterising ‘essential use’	1-May-20
Sub-contracting stakeholder feedback study	1-Jul-20
Solicit stakeholder feedback	1-Sep-20
Consult PFAS project group regarding criteria and stakeholder feedback	1-Dec-20
Decide on core criteria for essential use’ used in dossier	1-Dec-20
Apply criteria for determining essential and non-essential PFASs uses	1-Dec-20
Assess substance properties (P, B, T, (M))	1-Sep-20
Develop conceptual cost-effectiveness analysis approach for proportionality assessment	1-Sep-20
Define relevant impact categories	1-Sep-20
Approach for assessing emissions and stock pollution	1-Sep-20
Approach for monetising compliance costs per sector/use	1-Sep-20
Decide on uses to include in impact assessment	1-Jan-21
Formulate questions for call for evidence	1-Nov-20
Decide for which uses or sectors of use market information + PFAS emissions to environment is required	1-Dec-20
Call for tender market analysis	1-Mar-21
Define baseline scenario	1-Apr-21
Define restriction scenarios and derogations	1-Apr-21
Call for evidence alternatives, analyse alternatives	1-Nov-20
Collect relevant information on uses	1-Feb-21
Categorise uses for market analysis	1-Feb-21
Subcontract market analysis	1-Feb-21
Conclude on cost estimates used in CEA	1-Jul-21
Literature survey scientific and regulatory approaches to env. impact assessment for PBT/vPvB/PMT chemicals	1-Feb-21
Decide how results from literature survey can be used in restriction dossier	1-Feb-21
Decide on approach for assessing T	1-Feb-21
Subcontract emission assessment per use category	1-Feb-21
Emission and stock pollution assessment (per use category)	1-Feb-21
Conclude on environmental impacts	1-Feb-21
Literature survey scientific and regulatory approaches to health impact assessment for PBT/vPvB/PMT chemicals	1-Feb-21
Decide how results from literature survey can be used in restriction dossier	1-Feb-21
Decide on approach for assessing T	1-Feb-21
Subcontract emission assessment per use category	1-Feb-21
Qualitative and semi-quantitative assessment of health impacts	1-Feb-21
Conclude on (most relevant) health impacts	1-Feb-21
Categorise and structure other impacts	1-Feb-21
Subcontract assessment of other impacts per use category	1-Feb-21
Qualitative and semi-quantitative assessment of other impacts	1-Feb-21
Conclude on (most relevant) health impacts	1-Feb-21
Define SEA scenarios corresponding to impact assessment	1-Sep-21
Define benchmarks based on costs and discuss options for determining benchmarks based on effects	1-Sep-21

Present CEA results	1-Sep-21
Use information on health impacts to support proportionality assessment	1-Sep-21
Sensitivity analysis	1-Sep-21

Ends	Remarks	New deadline	Status
			Ongoing
30-Apr-20			Complete
30-Mar-20			Complete
			Complete
15-Apr-20			Complete
			Complete
17-Apr-20			
4/20/2020			Complete
24-Apr-20			Complete
27-Apr-20			Complete
30-Jul-20			Complete
Mid-November 2020			In progress
24-Aug-20			Complete
28-Sep-20			Ongoing
			Ongoing
ptember 2020			
Oct-20			Complete
ctober 2020			
2-Oct-20			Complete
24-Sep-20			Ongoing
2-Oct-20			Complete
23-Oct-20			
16-Oct-20			Not started
23-Oct-20			Not started
20-Nov-20			Not started
9-Nov-20			Not started
20-Nov-20			Not started
vember 2020			Not started
1-Jan-21			Not started
28-Jan-21			Not started
29-Jan-21			
June 2020			Complete
31-Aug-20			Complete
Sep-20			Complete
October 2020			Complete



October 2020	Complete	
31-Dec-20	In progress	
28 May 2020	Complete	M
Quarterly		
Monthly from Sept 2020		
Monthly from Sept 2020		
31 Oct 2020	Not in time	
Q4 2021	Started	
30-Jun-20	Complete	
	Complete	
31-Jul-20		
31-Aug-20	Complete	
1-Aug-20	Complete	
31-Oct-20	In progress	
~~31-Dec-20~~	~~In progress~~	
~~31-Oct-20~~	~~In progress~~	
~~November/December 2020~~	~~Not started~~	
Apr-21	In progress	
31-Jul-21	Not started	
31-Jul-21	Not started	
30-Jun-21		
31-Dec-21	Not started	
summer 2021	Not started	
10/1/2020	Complete	
10/15/2020	Complete	
	Complete	
	Not started	
	Not started	
	Not started	
	Not started	
	Not started	

31-Jul-20	Complete
31-Jul-20	In progress
31-Jul-20	In progress
31-Dec-20	In progress
31-Dec-20	Not started
31-Jan-21	Not started
31-Jan-21	Not started
31-Jan-21	Not started
31-Jan-21	Not started
31-Jan-21	Not started
31-Jan-21	Not started
31-Jan-21	Not started
28-Feb-21	Not started
31-Dec-20	Not started
28-Feb-21	Not started
30-Apr-21	Not started
30-Apr-21	Not started
30-Apr-21	Not started
31-Mar-21	Not started
31-Jul-21	Not started
31-Jul-21	Not started
31-Jul-21	Not started
31-Jul-21	
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
31-Aug-21	Not started
30-Nov-21	Not started
30-Nov-21	Not started

30-Nov-21	**Not started**
30-Nov-21	**Not started**
30-Nov-21	**Not started**


2021
6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12
M M M M M M M M M M M M M M M M M M M M


M M M M M
M M M M M M M M M M M M M M M
M M M M M M M M M M M M M M M




2022
1 2 3 4 5 6 7 8 9 10 11 12
M M M M M M M M M M M M





Remarks
M (meeting), D (draft document), F (final document), X (activity ongoing)



WP	Products	1	2	3
WP1	Preparation of Call for Evidence (including questionnaire and information document) in agreement between MS			
	Call for Evidence (all MS and ECHA with news alerts and websites of all MS with Link to Helpdesk webpage)			
	Preparation of Restriction option analysis document (all MS)			
	RIME+ Dortmund			
	1st draft of restriction option analysis document (all MS)			
	2nd draft of restriction option analysis document (all MS)			
	Finalisation of document, i.e. clarification of restriction options and scope (all MS)			
	Restriction option analysis document to be uploaded on CIRCA (DE/ NL CA)			
	RMOA-Conclusion, PACT-Update			
WP2	1st discussion paper prepared by NL			
	Face-to-face meeting (NL, DE, SE, DK, NO, ECHA, COM) based on discussion paper			
	2nd discussion paper prepared by NL (before RiME+)			
	Discussion during RiME+ meeting			
	Final discussion paper prepared by NL			
WP3	Kick-Off Meeting			
[X = deadline according to workplan]	**Pre-phase for environmental and human health hazard assessment --> Overview of relevant hazards (besides persistence) and generation of draft lists of substances for assessment**			
	Identification of arrowhead substances, degradation and biotransformation pathways, known and so far identified chemical alternatives			
	Add/Consider ECHA-database screening results			
	Literature search for hazard data			
	Consideration of relevant information from CfE (WP1) and surveys on uses (WP4)			
	Co-ordination with sub-use WP4's on following up on hazard information for PFAS and alternatives			
	Overview of relevant hazards			
	Generation of list of PFASs (and/or precursors, metabolites, read across substances) with available hazard data			
	Generation of list of chemical alternatives with available hazard data			

	Meeting (WP3 and WP2): to discuss hazards supporting scope, to discuss lead substances/substance classes/arrowheads to be used as examples, to define and limit the (sub)groups of substances			
	Meeting (WP3 and sub-WP4s): alignment on alternatives			
	Addition of results from consultation and follow up in sub-WP4s, in relation to both PFAS and alternatives			
	Identification of lead substances/substance groups to be assessed (draft list)			
	Identification of alternatives to be assessed (draft list)			
	Assessment phase --> Draft text for restriction proposal			
	Refinement of draft lists for assessment			
	Allocation of lead sustances/substance groups to MS			
	Draft summaries for relevant endpoints (PFAS)			
	Draft summaries for relevant endpoints (alternatives)			
	Alignment of draft summaries and assessment			
	Finalisation of assessment			
WP4	Start up, Develop generic information basis for all sub-uses, structure of the sub-use reports (by WP7) - DONE			
	Kick-off meeting (Discussion of content of each sub-use to avoid overlaps and discussion of revision of list of sub-uses and discussion of ETH Zürich work) - DONE			
	Start up sub uses, Project plan fine tuning for sub-uses (and if needed tendering for consultants)			
	Progress meeting after CfE is closed to check sub-uses, decide on stakeholder meetings (i.e. via mail)			
	Stakeholder Meetings per sub-use: Follow up on information from CfE and to address knowledge gaps			
	Sub-use studies (including gap analysis)			
	Progress meeting			
	Progress meeting			
	Final reports consultants			
	WP4. A (firefighting foams) = Comm/ECHA			
	WP4.B (SE, textiles) = Wood			

	WP4.C (NL, FCM) = Exponent			
	WP4.D (DE, consumer mixtures)			
	WP4.E (DK, lubricants and construction) = Wood/Cowi			
	WP4. F (SE, cosmetics) = Stockholm University			
	WP4. G (NL, production) = RPA			
	WP4. H (DE, chrome plating)			
	WP4.J (NO, ski wax) = Wood			
	WP4.M (NO, petroleum and mining) = Wood			
	WP4.N (NL, medical) = ■■ ■■			
	WP4.P (NO, F-gases) = Exponent			
	WP4.L (DE, Transportation)			
	WP4. R (DE, Electronics) = Haskoning or RPA			
	WP4. T (NL, waste) = Tauw or Ramboll			
	Integration of information (including gap analysis)			
	Additional studies			
	Preparation of the Annexes to the restriction dossier			
WP5	Overview analytical methods (ch E7)			
WP6	Overview human and environmental monitoring data			
WP7	Scoping essential use			
	Scoping impact assessment			
	Baseline and restriction scenario(s)			
	Economic impact assessment			
	Environmental impact assessment			
	Health impact assessment			
	Assessment of other impacts			
	Proportionality analysis			

			202						
4	**5**	**6**	**7**	**8**	**9**	**10**	**11**	**12**	**1**
						X		**Dec: not finished yet, still in progress**	
				X				Status: in progress	
				X					
				X				Status: in progress	
				X					
				X				Status: not started	
					X			Status: in progress	
					X			Status: in progress	
					X			Status: not started	

					X			Status: not started	
					?			Status: not started	
						X	X	Status: not started	
						X		Status: in progress	
						X		Status: not started	
							X	Status: not started	
							X	Status: in progress	
								Status: started	
								Status: not started	
								Status: not started	
								Status: not started	
								draft	
								draft	

								draft	
								draft	
								draft	?
								draft	
								draft	
								draft	
								draft	
								draft	
								draft	
								draft	

202

2	3	4	5	6	7	8	9	10	11

		X							
								X	
					X				
								X	X

?									
?									
draft									
	draft?								
draft									

202

12	1	2	3	4	5	6	7	8	9

X									
x									

10	11	12

Column2
Complete
In progress
In time
Not in time
Not started
Started
Unknown